Pure MHC is a leading discovery and development company focused on identifying novel HLA peptide targets for oncology, infectious disease, and autoimmune indications.

Using a proprietary methodology, Pure MHC qualifies and quantifies the surface presence of HLA peptide targets using primary tissues and provides them to partners for therapeutic development. De novo discovery projects as well as an assortment of well-profiled targets for colorectal (CRC), non-small cell lung (NSCLC), and ovarian cancers are available now.